| Document |
Document Title |
|
WO/2024/086317A1 |
The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cognitive impairment.
|
|
WO/2024/083670A2 |
The invention relates to bromine- or iodine-para-substituted [(1,5-diphenyl-1H-1,2,4-triazol-3-yl)oxy]acetic acid derivatives and their salts, to agents for protecting useful plants or crop plants comprising them, to methods for producin...
|
|
WO/2024/083671A1 |
The invention relates to bromine- or iodine-para-substituted [(1,5-Diphenyl-1H-1,2,4-triazol-3-yl)oxy]acetic acid derivatives and salts thereof, protection agents comprising them, for useful plants or crop plants, and methods for produci...
|
|
WO/2024/081311A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition or degradation of Cbl-b, and the treatment of Cbl-b-mediated disorders. Formula (I)
|
|
WO/2024/078646A1 |
A method for preparing (R)-tebuconazole by means of an enzyme chemical process, comprising: firstly, by taking the whole cell of recombinant bacterium E. coli/Rpeh expressing an epoxide hydrolase as a catalyst, resolving a racemic tebuco...
|
|
WO/2024/075825A1 |
The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity.　The present invention pertains to a cyclopentane compound represented by formula (I) or a pharmacologically acceptable salt th...
|
|
WO/2024/074126A1 |
Provided are a 4-methylsulfonylbenzamide compound having a structure represented by general formula (I) and having a sulfur-containing substituent at position 3, a stereoisomer thereof, an agriculturally acceptable salt thereof, a prepar...
|
|
WO/2024/077292A2 |
Described are synthetic compounds having anti-inflammatory properties and optionally analgesic properties. These compounds are derivatives of FDA-approved anti-inflammatory, such as ibuprofen and indomethacin, and can be formed using rea...
|
|
WO/2024/067784A1 |
Provided are an amorphous form and 16 crystal forms of a compound represented by formula (I). The crystal forms are named in order from crystal form A to crystal form P. Also provided is a preparation method for the amorphous form and po...
|
|
WO/2024/062363A1 |
The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as CBL-b inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and...
|
|
WO/2024/064778A2 |
The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R1, X, and n are defined herein, their pharmaceutical compositions, and methods of use for treating diseases that are vulnerab...
|
|
WO/2024/063147A1 |
The present invention provides a compound represented by formula (I) and useful as a pharmaceutical product, or a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition for the treat...
|
|
WO/2024/057213A1 |
The present invention relates to a process for preparation of Ipconazole and its intermediates. The present invention provides a simple, cost-effective and industrially viable process for preparation of Ipconazole and its intermediates. ...
|
|
WO/2024/050815A1 |
Provided is the use of heteroaromatic ring compounds in nucleic acid tests. Particularly provided are the use of heteroaromatic ring compounds as a nucleic acid protective agent in nucleic acid tests, a method for inhibiting degradation ...
|
|
WO/2024/044813A1 |
The present invention relates to novel fluoroallylamine sulfone derivatives that are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for the treatment of a variety of indications, e.g., fibrosis, cancer an...
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
|
WO/2024/031192A1 |
Provided herein is the synthesis of a folate phosphoramidite of Formula I and the use of the folate phosphoramidite in the preparation of folate-siRNAs. Also provided are methods to silent expression of a target gene in a cell that expre...
|
|
WO/2024/028363A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2024/028364A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2024/028169A1 |
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...
|
|
WO/2024/030960A2 |
Methods and systems and compounds and agents for the induction or modulation of ferroptosis in a cell, a tissue, or a tumor in a subject are provided. Various agents and compounds are described. Various methods of administration are desc...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/025797A1 |
A composition includes at least one pH adjuster, at least one chelating agent, at least one anionic surfactant, at least one nitrogen containing heterocycle, at least one alkylamine compound, and an aqueous solvent, wherein the compositi...
|
|
WO/2024/024866A1 |
[Problem] The present invention provides: a water-based coating composition containing an ultraviolet ray absorber, which has excellent transparency and satisfactorily blocks ultraviolet ray; and a method for producing the water-based co...
|
|
WO/2024/025907A1 |
The present disclosure provides compounds of Formula (IA) and their pharmaceutical compositions: The compounds and compositions are useful for inhibiting the activity of plasma kallikrein, and they are useful in therapy and in methods of...
|
|
WO/2024/019014A1 |
Provided as a precursor of a radioactive halogen-labeled compound is a compound represented by general formula (I) [in the formula, R1 represents a leaving group that can undergo nucleophilic substitution by a halide ion, R2 represents a...
|
|
WO/2024/017150A1 |
Provided in the present application is a method for synthesizing deucravacitinib. The method comprises: subjecting the compound of formula (I) to chlorination and to electrophilic substitution with the compound of formula (VI) to synthes...
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/014430A1 |
The present invention addresses the problem of providing a method for producing an amino lipid compound that has improved yield in a carbonate esterification reaction and to provide an intermediate compound to be used in the abovemention...
|
|
WO/2024/012537A1 |
The present invention relates to the technical field of new pesticide compounds, and disclosed are a compound containing a triazolinone structure, and the use thereof and an herbicide. The compound has the structure as represented by for...
|
|
WO/2024/015861A1 |
Provided herein are methods of preparation of compound 101. Also provided are intermediate compounds useful in the preparation of compound 101, and methods of preparation of those intermediate compounds.
|
|
WO/2024/014282A1 |
Provided is a method for producing a triazole derivative enantiomer (R). The method includes: a step for adding, in a solvent, a chiral molecule represented by general formula (IIa) or general formula (IIb) to a triazole derivative repre...
|
|
WO/2024/010776A1 |
The present disclosure features agents that bind and stabilize transcription factors of interest.
|
|
WO/2024/009691A1 |
The present invention provides: a nonaqueous electrolyte solution which comprises (I) at least one compound that is selected from the group consisting of compounds represented by general formula (1), compounds represented by general form...
|
|
WO/2024/009283A1 |
Angiotensin AT2 receptor antagonists have been clinically validated for the treatment of chronic neuropathic pain. We discovered a series of lead compounds comprising a trisubstituted heterocyclic core that show high in vitro (sub-nanomo...
|
|
WO/2023/247239A1 |
The present invention relates to a method for producing 2-[4-(4-chlorophenoxy)-2- (trifluoromethyl)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol in high purity and yield.
|
|
WO/2023/250181A1 |
Provided is a compound having the structure of Formula (1) or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, Ri, R2, R3, R4, R5, R6, R7, m, 11, p, and y are as defined herein, for use in methods fo...
|
|
WO/2023/247966A1 |
The present disclosure relates to copper-catalysed cycloaddition reactions. In particular, the use of copper-catalysed cycloaddition reactions in bioconjugation reactions, e.g. bioconjugation reactions involving the use of an ynamine as ...
|
|
WO/2023/247712A1 |
The present invention relates to substituted 1,2,3-triazoles of formula (I) useful for the treatment of ocular diseases, in particular those related to retinal degeneration. The invention also relates to pharmaceutical compositions to tr...
|
|
WO/2023/245156A2 |
The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse/addiction and withdrawal therefrom comprising administeri...
|
|
WO/2023/241314A1 |
The present disclosure relates to a type of novel lipid compound and a use thereof, and specifically relates to a type of novel lipid compound and to a lipid nanodelivery carrier comprising the compound; the compound has improved biocomp...
|
|
WO/2023/236824A1 |
The present application provides a dendron-like lipid compound, a liposome, a lipid complex, and a lipid nanoparticle and a use thereof. The dendron-like lipid compound is selected from any one of structures represented by formulas I-III...
|
|
WO/2023/239909A1 |
Exemplary methods are directed to synthesizing an aryltriazole. An exemplary method may include mixing a weak acid with water to generate a first mixture; mixing an ortho-aryldiamine into the first mixture to generate a second mixture; h...
|
|
WO/2023/232519A1 |
The present invention relates to a chemical compound according to general formula (1).
|
|
WO/2023/235384A1 |
Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of enhancing readthrough of genes containing premature termina...
|
|
WO/2023/226344A1 |
An ionic liquid composition and a preparation method therefor. The ionic liquid composition comprises the following components in percentages by weight: 80-90% of ionic liquid A, and 10-20% of ionic liquid B. By compounding the ionic liq...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/213785A1 |
The presently claimed invention is directed to a product, or a salt thereof obtainable by a process comprising at least the step of: a) reacting at least one compound of formula (I) wherein G* is selected from formula (A), or formula (B)...
|
|
WO/2023/209191A1 |
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a di...
|
